| 臺大學術典藏 |
2022-01-24T09:31:17Z |
Profile and value of FIB-4 in patients with dual chronic hepatitis C and B
|
CHUN-JEN LIU; Tseng T.-C.; Yang W.-T.; Su T.-H.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:16Z |
Chronic hepatitis B is associated with an increased risk of B-cell non-Hodgkin's lymphoma and multiple myeloma
|
Su T.-H.; CHUN-JEN LIU; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:16Z |
Early antiviral therapy reduces the risk of lymphoma in patients with chronic hepatitis C infection
|
Su T.-H.; CHUN-JEN LIU; Tseng T.-C.; Chou S.-W.; Liu C.-H.; Yang H.-C.; Wu S.-J.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:16Z |
Efficacy and safety of 12 weeks of daclatasvir, asunaprevir plus ribavirin for HCV genotype-1b infection without NS5A resistance-associated substitutions
|
Yu M.-L.; Hung C.-H.; Huang Y.-H.; Peng C.-Y.; Lin C.-Y.; Cheng P.-N.; Chien R.-N.; Hsu S.-J.; Liu C.-H.; Huang C.-F.; Su C.-W.; Huang J.-F.; CHUN-JEN LIU; Kao J.-H.; Chuang W.-L.; Chen P.-J.; Chen D.-S. |
| 臺大學術典藏 |
2022-01-24T09:31:13Z |
Sofosbuvir-based direct acting antiviral therapies for patients with hepatitis C virus genotype 2 infection
|
Liu C.-H.; Su T.-H.; CHUN-JEN LIU; Hong C.-M.; Yang H.-C.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:13Z |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis
|
Liu C.-H.; Shih Y.-L.; Yang S.-S.; Lin C.-L.; Fang Y.-J.; Cheng P.-N.; Chen C.-Y.; Peng C.-Y.; Hsieh T.-Y.; Chiu Y.-C.; Su T.-H.; CHUN-JEN LIU; Yang H.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:12Z |
NIACE score refines the overall survival of hepatocellular carcinoma by Barcelona clinic liver cancer staging
|
Su T.-H.; Liao S.-H.; Hong C.-M.; CHUN-JEN LIU; Tseng T.-C.; Liu C.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Adhoute X.; Bourli?re M.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:12Z |
High Level of Hepatitis B Core–Related Antigen Associated With Increased Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection of Intermediate Viral Load
|
Tseng T.-C.; CHUN-JEN LIU; Hsu C.-Y.; Hong C.-M.; Su T.-H.; Yang W.-T.; Chen C.-L.; Yang H.-C.; Huang Y.-T.; Fang-Tzu Kuo S.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:12Z |
Antiviral Therapy in Patients With Chronic Hepatitis C Is Associated With a Reduced Risk of Parkinsonism
|
Su T.-H.; Yang H.-C.; Tseng T.-C.; Chou S.-W.; Lin C.-H.; Liu C.-H.; CHUN-JEN LIU; Chen C.-L.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:11Z |
Sofosbuvir/velpatasvir with or without low-dose ribavirin for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; Tseng K.-C.; Lo C.-C.; CHUN-JEN LIU; Chen J.-J.; Peng C.-Y.; Shih Y.-L.; Yang S.-S.; Huang C.-S.; Huang K.-J.; Chang C.-Y.; Tsai M.-C.; Kao W.-Y.; Fang Y.-J.; Chen P.-Y.; Su P.-Y.; Tseng C.-W.; Huang J.-J.; Lee P.-L.; Lai H.-C.; Hsieh T.-Y.; Chang C.-H.; Huang Y.-J.; Lee F.-J.; Chang C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:11Z |
Serum Mac-2-Binding Protein Glycosylation Isomer at Virological Remission Predicts Hepatocellular Carcinoma and Death in Chronic Hepatitis B-Related Cirrhosis
|
Su T.-H.; Peng C.-Y.; Tseng T.-C.; Yang H.-C.; CHUN-JEN LIU; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:10Z |
Baseline Mac-2 Binding Protein Glycosylation Isomer Level Stratifies Risks of Hepatocellular Carcinoma in Chronic Hepatitis B Patients with Oral Antiviral Therapy
|
Tseng T.-C.; Peng C.-Y.; Hsu Y.-C.; Su T.-H.; Wang C.-C.; CHUN-JEN LIU; Yang H.-C.; Yang W.-T.; Lin C.-H.; Yu M.-L.; Lai H.-C.; Tanaka Y.; Nguyen M.H.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:10Z |
Evolution of eGFR in chronic HCV patients receiving sofosbuvir-based or sofosbuvir-free direct-acting antivirals
|
Liu C.-H.; Lee M.-H.; Lin J.-W.; CHUN-JEN LIU; Su T.-H.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:10Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection: Real-world effectiveness and safety in Taiwan
|
Liu C.-H.; CHUN-JEN LIU; Hung C.-C.; Hsieh S.-M.; Su T.-H.; Sun H.-Y.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:09Z |
HEV superinfection accelerates disease progression in patients with chronic HBV infection and increases mortality in those with cirrhosis
|
Tseng T.-C.; CHUN-JEN LIU; Chang C.T.; Su T.-H.; Yang W.-T.; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:09Z |
Glecaprevir/pibrentasvir for patients with chronic hepatitis C virus infection and severe renal impairment
|
Liu C.-H.; Yang S.-S.; Peng C.-Y.; Lin W.-T.; CHUN-JEN LIU; Su T.-H.; Tseng T.-C.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:08Z |
2020 Taiwan consensus statement on the management of hepatitis C: part (I) general population
|
Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; CHUN-JEN LIU; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L. |
| 臺大學術典藏 |
2022-01-24T09:31:07Z |
2020 Taiwan consensus statement on the management of hepatitis C: Part (II) special populations
|
Yu M.-L.; Chen P.-J.; Dai C.-Y.; Hu T.-H.; Huang C.-F.; Huang Y.-H.; Hung C.-H.; Lin C.-Y.; Liu C.-H.; CHUN-JEN LIU; Peng C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L. |
| 臺大學術典藏 |
2022-01-24T09:31:06Z |
Antiviral therapy against chronic hepatitis C is associated with a reduced risk of oral cancer
|
Su T.-H.; Tseng T.-C.; CHUN-JEN LIU; Chou S.-W.; Liu C.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chen C.-L.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:06Z |
Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C in Taiwan: Real-world data
|
Hong C.-M.; Liu C.-H.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen Y.-W.; Kao J.-H.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-24T09:31:05Z |
Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
|
Huang C.-F.; Lai H.-C.; Chen C.-Y.; Tseng K.-C.; Kuo H.-T.; Hung C.-H.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; Kao J.-H.; CHUN-JEN LIU; Liu C.-H.; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:31:04Z |
Successful antiviral therapy reduces risk of schizophrenia among chronic hepatitis c patients: A nationwide real-world Taiwanese cohort (T-COACH)
|
Tsai P.-C.; Chen C.-Y.; Kuo H.-T.; Hung C.-H.; Tseng K.-C.; Lai H.-C.; Peng C.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Kao J.-H.; CHUN-JEN LIU; Liu C.-H.; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Tai C.-M.; Lin C.-W.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang C.-F.; Hsieh M.-H.; Huang J.-F.; Dai C.-Y.; Chung W.-L.; Ke C.-L.K.; Yu M.-L.; T-COACH Study Group |
| 臺大學術典藏 |
2022-01-24T09:31:03Z |
Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis
|
Hsu W.-F.; Chen C.-Y.; Tseng K.-C.; Lai H.-C.; Kuo H.-T.; Hung C.-H.; Tung S.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Lin C.-Y.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; Kao J.-H.; CHUN-JEN LIU; Liu C.-H.; Yan S.-L.; Bair M.-J.; Su W.-W.; Chu C.-H.; Chen C.-J.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Tsai P.-C.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Yu M.-L.; Peng C.-Y. |
| 臺大學術典藏 |
2022-01-24T09:31:03Z |
High risk of clinical relapse in patients with chronic Hepatitis B virus infection after cessation of prophylactic antiviral therapy for rituximab-containing chemotherapy
|
Chang W.-Y.; Chiu Y.-C.; Chiu F.-W.; Hsu Y.-C.; Tseng T.-C.; Cheng P.-N.; Yang S.-S.; CHUN-JEN LIU; Su T.-H.; Yang H.-C.; Liu C.-H.; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:02Z |
Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan
|
Liu C.-H.; Su T.-H.; CHUN-JEN LIU; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:02Z |
Elbasvir/grazoprevir for hepatitis C virus genotype 1b East-Asian patients receiving hemodialysis
|
Liu C.-H.; Peng C.-Y.; Fang Y.-J.; Kao W.-Y.; Yang S.-S.; Lin C.-K.; Lai H.-C.; Su W.-P.; Fang S.-U.; Chang C.-C.; Su T.-H.; CHUN-JEN LIU; Chen P.-J.; Chen D.-S.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:01Z |
Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents
|
Huang S.-C.; Cheng P.-N.; Liu C.-H.; Yang H.-C.; Su T.-H.; Tseng T.-C.; Chen P.-J.; Kao J.-H.; CHUN-JEN LIU |
| 臺大學術典藏 |
2022-01-24T09:31:01Z |
Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis
|
Su T.-H.; Peng C.-Y.; Chang S.-H.; Tseng T.-C.; CHUN-JEN LIU; Chen C.-L.; Liu C.-H.; Yang H.-C.; Chen P.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:31:00Z |
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
|
Huang C.-F.; Tseng K.-C.; Cheng P.-N.; Hung C.-H.; Lo C.-C.; Peng C.-Y.; Bair M.-J.; Yeh M.-L.; Chen C.-H.; Lee P.-L.; Lin C.-Y.; Kuo H.-T.; Chen C.-T.; Yang C.-C.; Huang J.-F.; Tai C.-M.; Hu J.-T.; Lin C.-L.; Su W.-W.; Tsai W.-L.; Huang Y.-H.; Cheng C.-Y.; Lin C.-L.; Wang C.-C.; Yang S.-S.; Mo L.-R.; Chen G.-Y.; Chang C.-C.; Wang S.-J.; Huang C.-S.; Hsieh T.-Y.; Lin C.-W.; Lee T.-H.; Chong L.-W.; Huang C.-W.; Chang S.-N.; Tsai M.-C.; Hsu S.-J.; Kao J.-H.; CHUN-JEN LIU; Liu C.-H.; Lin H.-C.; Lee M.-H.; Tsai P.-C.; Dai C.-Y.; Chuang W.-L.; Chen C.-Y.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:31:00Z |
Hepatitis C virus reinfection in patients on haemodialysis after achieving sustained virologic response with antiviral treatment
|
Liu C.-H.; Peng C.-Y.; Kao W.-Y.; Yang S.-S.; Shih Y.-L.; Lin C.-L.; Tsai M.-K.; Lee C.-Y.; Chang C.-C.; Wu J.-H.; CHUN-JEN LIU; Su T.-H.; Tseng T.-C.; Chen P.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:59Z |
Sofosbuvir/Velpatasvir for Hepatitis?C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan
|
Cheng P.-N.; Mo L.-R.; Chen C.-T.; Chen C.-Y.; Huang C.-F.; Kuo H.-T.; Lo C.-C.; Tseng K.-C.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Chang T.S.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Chou K.-H.; Kao C.-N.; Tsai P.-C.; Liu C.-H.; Lee M.-H.; Cheng C.-Y.; Tsai M.-C.; CHUN-JEN LIU; Dai C.-Y.; Lin H.-C.; Kao J.-H.; Chuang W.-L.; Yu M.-L.; TACR investigators |
| 臺大學術典藏 |
2022-01-24T09:30:58Z |
Sofosbuvir/velpatasvir for patients with chronic hepatitis C virus infection and compensated liver disease: real-world data in Taiwan
|
Liu C.-H.; Chen P.-Y.; Chen J.-J.; Lo C.-C.; Su W.-W.; Tseng K.-C.; CHUN-JEN LIU; Huang C.-S.; Huang K.-J.; Yang S.-S.; Peng C.-Y.; Tsai M.-C.; Kao W.-Y.; Chang C.-Y.; Shih Y.-L.; Fang Y.-J.; Chen C.-Y.; Lee P.-L.; Huang J.-J.; Su P.-Y.; Tseng C.-W.; Hung C.-C.; Chang C.-H.; Huang Y.-J.; Lai H.-C.; Chang C.-C.; Lee F.-J.; Hsieh T.?Y.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:58Z |
Serum hepatitis B core-related antigen level stratifies risk of disease progression in chronic hepatitis B patients with intermediate viral load
|
Tseng T.-C.; CHUN-JEN LIU; Yang W.-T.; Hsu C.-Y.; Hong C.-M.; Su T.-H.; Tsai C.-H.; Chen C.-L.; Yang H.-C.; Liu C.-H.; Chen H.-H.; Chen P.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:57Z |
Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan
|
Chen C.-Y.; Huang C.-F.; Cheng P.-N.; Tseng K.-C.; Lo C.-C.; Kuo H.-T.; Huang Y.-H.; Tai C.-M.; Peng C.-Y.; Bair M.-J.; Chen C.-H.; Yeh M.-L.; Lin C.-L.; Lin C.-Y.; Lee P.-L.; Chong L.-W.; Hung C.-H.; Huang J.-F.; Yang C.-C.; Hu J.-T.; Lin C.-W.; Chen C.-T.; Wang C.-C.; Su W.-W.; Hsieh T.-Y.; Lin C.-L.; Tsai W.-L.; Lee T.-H.; Chen G.-Y.; Wang S.-J.; Chang C.-C.; Mo L.-R.; Yang S.-S.; Wu W.-C.; Huang C.-S.; Hsiung C.-K.; Kao C.-N.; Tsai P.-C.; Liu C.-H.; Lee M.-H.; CHUN-JEN LIU; Dai C.-Y.; Kao J.-H.; Chuang W.-L.; Lin H.-C.; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:30:56Z |
Evolution of estimated glomerular filtration rate in human immunodeficiency virus and hepatitis C virus-coinfected patients receiving sofosbuvir-based direct-acting antivirals and antiretroviral therapy
|
Liu C.-H.; Sun H.-Y.; Hsieh S.-M.; Liu W.-C.; Sheng W.-H.; CHUN-JEN LIU; Su T.-H.; Tseng T.-C.; Chen P.-J.; Hung C.-C.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-24T09:30:55Z |
Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan
|
Hsieh M.-H.; Bair M.-J.; Tsai P.-C.; Tseng K.-C.; Lo C.-C.; Chen C.-Y.; Kuo H.-T.; Hung C.-H.; Lai H.-C.; Peng C.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Kao J.-H.; CHUN-JEN LIU; Liu C.-H.; Yan S.-L.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Tai C.-M.; Lin C.-W.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Yeh M.-L.; Huang C.-F.; Huang J.-F.; Dai C.-Y.; Yu M.-L.; Chuang W.-L.; T-COACH investigators |
| 臺大學術典藏 |
2022-01-24T09:30:54Z |
Hepatitis C virus eradication decreases the risks of liver cirrhosis and cirrhosis-related complications (Taiwanese chronic hepatitis C cohort)
|
Hsu W.-F.; Tsai P.-C.; Chen C.-Y.; Tseng K.-C.; Lai H.-C.; Kuo H.-T.; Hung C.-H.; Tung S.-Y.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Lin C.-Y.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; Kao J.-H.; CHUN-JEN LIU; Liu C.-H.; Yan S.-L.; Bair M.-J.; Su W.-W.; Chu C.-H.; Chen C.-J.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Yu M.-L.; Peng C.-Y. |
| 臺大學術典藏 |
2022-01-24T09:30:53Z |
Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)
|
Yeh M.-L.; Hung C.-H.; Tseng K.-C.; Lai H.-C.; Chen C.-Y.; Kuo H.-T.; Wang J.-H.; Chen J.-J.; Lee P.-L.; Chien R.-N.; Yang C.-C.; Lo G.-H.; Tai C.-M.; Lin C.-W.; Kao J.-H.; Liu C.-H.; Yan S.-L.; Bair M.-J.; Lin C.-Y.; Su W.-W.; Chu C.-H.; Chen C.-J.; Tung S.-Y.; Lo C.-C.; Cheng P.-N.; Chiu Y.-C.; Wang C.-C.; Cheng J.-S.; Tsai W.-L.; Lin H.-C.; Huang Y.-H.; Huang C.-F.; Huang J.-F.; Dai C.-Y.; Chuang W.-L.; Tsai P.-C.; Peng C.-Y.; CHUN-JEN LIU; Yu M.-L. |
| 臺大學術典藏 |
2022-01-24T09:30:53Z |
Sofosbuvir/velpatasvir plus ribavirin for child-pugh b and child-pugh c hepatitis c virus-related cirrhosis
|
Liu C.-H.; Chen C.-Y.; Su W.-W.; CHUN-JEN LIU; Lo C.-C.; Huang K.-J.; Chen J.-J.; Tseng K.-C.; Chang C.-Y.; Peng C.-Y.; Shih Y.-L.; Huang C.-S.; Kao W.-Y.; Yang S.-S.; Tsai M.-C.; Wu J.-H.; Chen P.-Y.; Su P.-Y.; Hwang J.-J.; Fang Y.-J.; Lee P.-L.; Tseng C.-W.; Lee F.-J.; Lai H.-C.; Hsieh T.-Y.; Chang C.-C.; Chang C.-H.; Huang Y.-J.; Kao J.-H. |
| 臺大學術典藏 |
2022-01-11T06:49:25Z |
Recommendations for psoriatic arthritis management: A joint position paper of the Taiwan Rheumatology Association and the Taiwanese Association for Psoriasis and Skin Immunology
|
Tsai T.-F.; Hsieh T.-Y.; Chi C.-C.; Chou C.-T.; Hsieh L.-F.; Chen H.-H.; Hui R.C.-Y.; Lee C.-H.; Liu C.-H.; Liu H.-C.; Yeo K.-J.; Chen C.-H.; Chen H.-A.; Chen Y.-C.; Chen Y.-J.; HSIEN-YI CHIU; Ho J.-C.; Huang Y.-H.; Lai P.-J.; Lee W.-R.; Liao H.-T.; Lin S.-H.; Tseng J.-C.; Wang T.-S.; Wu N.-L.; Yang D.-H.; Tsai W.-C.; Wei J.C.-C.; Taiwan Rheumatology Association (TRA); the Taiwanese Association for Psoriasis; Skin Immunology (TAPSI) |
| 臺大學術典藏 |
2022-01-07T06:05:52Z |
Peginterferon alfa-2a with or without low-dose ribavirin for treatment-naive patients with hepatitis C virus genotype 2 receiving haemodialysis: A randomised trial
|
Liu C.-H.; Liu C.-J.; Huang C.-F.; Lin J.-W.; Dai C.-Y.; Liang C.-C.; Huang J.-F.; Hung P.-H.; Tsai H.-B.; Tsai M.-K.; CHIH-YUAN LEE; Chen S.-I.; Yang S.-S.; Su T.-H.; Yang H.-C.; Chen P.-J.; Chen D.-S.; Chuang W.-L.; Yu M.-L.; Kao J.-H. |
| 國立成功大學 |
2022 |
On-Site Investigations of Coastal Erosion and Accretion for the Northeast of Taiwan
|
Liang, T.-Y.;Chang, Chang C.-H.;Hsiao, S.-C.;Huang, W.-P.;Chang, T.-Y.;Guo, W.-D.;Liu, C.-H.;Ho, J.-Y.;Chen, W.-B. |
| 國立成功大學 |
2022 |
Topology Optimization Design and Experiment of a Soft Pneumatic Bending Actuator for Grasping Applications
|
Liu, C.-H.;Chen, L.-J.;Chi, J.-C.;Wu, J.-Y. |
| 國立成功大學 |
2022 |
Diabetic Patients With Rosacea Increase the Risks of Diabetic Macular Edema, Dry Eye Disease, Glaucoma, and Cataract
|
Wang, F.-Y.;Kang, E.Y.-C.;Liu, C.-H.;Ng, C.Y.;Shao, Shao S.-C.;Lai, E.C.-C.;Wu, Wu W.-C.;Huang, Y.-Y.;Chen, K.-J.;Lai, C.-C.;Hwang, Y.-S. |
| 國立成功大學 |
2022 |
Iridescent Colloidal Crystals Composed of SiO2Porous Hollow Sphere for SERS Application
|
Liu, C.-H.;Wei, M.-X.;Hsu, C.-H.;Lin, H.-P.;Wu, Y.-C. |
| 國立成功大學 |
2022 |
Detailed risks and characteristics of postepilepsy stroke in non-traumatic adult-onset epilepsy
|
Lin, P.-Y.;Liu, C.-H.;Chang, Y.-M.;Huang, C.-W.;Su, H.-C.;Lin, S.-H.;Sung, P.-S. |
| 國立成功大學 |
2022 |
Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents
|
Huang, S.-C.;Cheng, P.-N.;Liu, C.-H.;Yang, H.-C.;Su, T.-H.;Tseng, Tseng T.-C.;Chen, P.-J.;Kao, J.-H.;Liu, C.-J. |
| 國立成功大學 |
2022 |
Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4–6 infection: Real-world evidence from a nationwide registry in Taiwan
|
Lo, C.-C.;Huang, C.-F.;Cheng, P.-N.;Tseng, K.-C.;Chen, Chen C.-Y.;Kuo, H.-T.;Huang, Y.-H.;Tai, C.-M.;Peng, C.-Y.;Bair, M.-J.;Chen, Chen C.-H.;Yeh, M.-L.;Lin, C.-L.;Lin, C.-Y.;Lee, P.-L.;Chong, L.-W.;Hung, C.-H.;Chang, T.S.;Huang, J.-F.;Yang, C.-C.;Hu, J.-T.;Lin, C.-W.;Chen, Chen C.-T.;Wang, C.-C.;Su, W.-W.;Hsieh, T.-Y.;Lin, C.-L.;Tsai, W.-L.;Lee, T.-H.;Chen, G.-Y.;Wang, S.-J.;Chang, Chang C.-C.;Mo, L.-R.;Yang, S.-S.;Wu, Wu W.-C.;Huang, C.-S.;Hsiung, C.-K.;Kao, C.-N.;Tsai, P.-C.;Liu, C.-H.;Lee, M.-H.;Liu, C.-J.;Dai, C.-Y.;Chuang, W.-L.;Lin, H.-C.;Kao, J.-H.;Yu, M.-L.;investigators, TACR |
| 國立成功大學 |
2022 |
Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR)
|
Huang, C.-F.;Tseng, K.-C.;Cheng, P.-N.;Hung, C.-H.;Lo, C.-C.;Peng, C.-Y.;Bair, M.-J.;Yeh, M.-L.;Chen, Chen C.-H.;Lee, P.-L.;Lin, C.-Y.;Kuo, H.-T.;Chen, Chen C.-T.;Yang, C.-C.;Huang, J.-F.;Tai, C.-M.;Hu, J.-T.;Lin, C.-L.;Su, W.-W.;Tsai, W.-L.;Huang, Y.-H.;Cheng, Cheng C.-Y.;Lin, C.-L.;Wang, C.-C.;Yang, S.-S.;Mo, L.-R.;Chen, G.-Y.;Chang, Chang C.-C.;Wang, S.-J.;Huang, C.-S.;Hsieh, T.-Y.;Lin, C.-W.;Lee, T.-H.;Chong, L.-W.;Huang, C.-W.;Chang, S.-N.;Tsai, M.-C.;Hsu, S.-J.;Kao, J.-H.;Liu, C.-J.;Liu, C.-H.;Lin, H.-C.;Lee, M.-H.;Tsai, P.-C.;Dai, C.-Y.;Chuang, W.-L.;Chen, Chen C.-Y.;Yu, M.-L. |
| 國立成功大學 |
2022 |
Internet addiction and psychological distress among Chinese schoolchildren before and during the COVID-19 outbreak: A latent class analysis
|
Chen, I.-H.;Chen, Chen C.-Y.;Liu, C.-H.;Ahorsu, D.K.;Griffiths, M.D.;Chen, Y.-P.;Kuo, Y.-J.;Lin, C.-Y.;Pakpour, A.H.;Wang, S.-M. |
